Avalo Therapeutics Inc, a clinical-stage biotech firm based in Rockville, Maryland with 20 employees, focuses on developing therapies targeting the LIGHT-signaling network for immune dysregulation. Their key products include AVTX-002 for various disorders and AVTX-008, a BTLA agonist fusion protein, with the company going public in 2015.
AVTX filed a patent for "methods and treatment for adult-onset still's disease and systemic-onset juvenile idiopathic arthritis involving antibodies to il-18" on Mon, December 19, 2022. The patent was officially published on Thu, September 7, 2023.
📡️ Health Care
Patents
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
